AIMMUNE THERAPEUTICS
Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.
AIMMUNE THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2011-01-01
Address:
Brisbane, California, United States
Country:
United States
Website Url:
http://www.aimmune.com
Total Employee:
251+
Status:
Active
Contact:
+1 650 614 5220
Total Funding:
540 M USD
Technology used in webpage:
Domain Not Resolving IPv6 COVID-19 DigiCert SSL AWS Global Accelerator Akamai Hosted Visual Studio Akamai Edge Microsoft Authentication Library For JavaScript Contentful
Similar Organizations
Agile Therapeutics
Agile Therapeutics is pharmaceutical company developing contraceptive healthcare products for women.
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Certara
Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development.
Cleo
Cleo is a benefits platform that provides personalized guidance for working families.
Crinetics Pharmaceuticals
Crinetics is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics.
CureVac
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA.
Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.
Summit Therapeutics
Summit Therapeutics is a clinical-stage drug discovery and development company.
Trevena
Trevena is a clinical stage biopharmaceutical company discovering and developing G-protein coupled receptors (GPCR) biased ligands.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
Andrew Oxtoby President & Chief Executive Officer @ Aimmune Therapeutics
President & Chief Executive Officer
2020-10-01
Joe Cooper Acting CBO @ Aimmune Therapeutics
Acting CBO
Carol Zoltowski VP Regulatory Affairs @ Aimmune Therapeutics
VP Regulatory Affairs
Mary Rozenman SVP, Corporate and Commercial Development @ Aimmune Therapeutics
SVP, Corporate and Commercial Development
2015-04-08
Isabelle DeArmond CMO @ Aimmune Therapeutics
CMO
Sue Barrowcliffe General Manager Europe @ Aimmune Therapeutics
General Manager Europe
2016-01-01
Founder
Stock Details
Investors List
Nestlé Health Science
Nestlé Health Science investment in Post-IPO Equity - Aimmune Therapeutics
Nestlé Health Science
Nestlé Health Science investment in Post-IPO Equity - Aimmune Therapeutics
Nestlé Health Science
Nestlé Health Science investment in Post-IPO Equity - Aimmune Therapeutics
Foresite Capital
Foresite Capital investment in Series B - Aimmune Therapeutics
Aisling Capital
Aisling Capital investment in Series B - Aimmune Therapeutics
Longitude Capital
Longitude Capital investment in Series B - Aimmune Therapeutics
Adage Capital Management
Adage Capital Management investment in Series B - Aimmune Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Aimmune Therapeutics
Fidelity
Fidelity investment in Series B - Aimmune Therapeutics
Longitude Capital
Longitude Capital investment in Series A - Aimmune Therapeutics
Official Site Inspections
http://www.aimmune.com Semrush global rank: 4.79 M Semrush visits lastest month: 1.87 K
- Host name: a11472d5bbcc1c369.awsglobalaccelerator.com
- IP address: 99.83.129.68
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Aimmune Therapeutics"
Nestlé completes acquisition of Aimmune Therapeutics
Oct 14, 2020 Nestlé announced today the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT). Joining Nestlé Health Science (NHSc) as a stand-alone …See details»
Press Release - Nestlé Global
Nestlé and Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies …See details»
Aimmune Therapeutics - LinkedIn
Aimmune Therapeutics, Inc., a Nestlé Health Science Company, is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies.See details»
Aimmune Therapeutics - Crunchbase Company Profile …
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.See details»
Nestlé completes acquisition of Aimmune Therapeutics
Oct 14, 2020 Acquisition of Aimmune Therapeutics marks an important milestone in constant pursuit of innovative science-based nutritional solutions. Discover more here.See details»
Nestlé makes newly acquired Aimmune a stand-alone unit, …
Oct 14, 2020 Nestlé has finished acquiring Aimmune Therapeutics, fashioning the food allergy treatment maker as a stand-alone unit with a new leadership team. Andrew Oxtoby, formerly …See details»
Aimmune Therapeutics Company Overview, Contact Details
Feb 5, 2020 Learn more about Aimmune Therapeutics's company details, contact information, competitors, and more. Find accurate contact data easily with LeadIQ. Book a demo today.See details»
Nestlé to acquire Aimmune Therapeutics
Nestlé and Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies …See details»
Nestlé to acquire Aimmune Therapeutics - Nestlé Global
Aug 31, 2020 Nestlé Health Science and Aimmune to create a global leader in food allergy prevention and treatment.See details»
Nestlé Health Science Invests in Aimmune Therapeutics | NHS
Feb 5, 2020 New investment of USD200 million Lausanne, Switzerland, February 5, 2020 -- Nestlé Health Science (NHSc) today announced that it will make a further equity investment of …See details»
Nestlé completes acquisition of Aimmune Therapeutic
Nestlé completes acquisition of Aimmune Therapeutics isition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT). Joining Nestlé Health Science (NHSc) as a stand-alone business unit called …See details»
Nestlé Health to acquire Aimmune Therapeutics for $2.6bn
Sep 1, 2020 Nestlé Health Science (NHSc) has signed an agreement to acquire biopharmaceutical company Aimmune Therapeutics for $2.6bn, or $34.50 per share, in cash.See details»
Aimmune Therapeutics - News, Articles etc. - European …
Sep 1, 2020 news Nestlé Health Science to acquire Aimmune Therapeutics for $2.6 billion 1 September 2020 | By Victoria Rees (European Pharmaceutical Review) Nestlé Health Science …See details»
Nestlé completes acquisition of Aimmune Therapeutics | Nasdaq
Oct 14, 2020 "Nestlé Health Science's acquisition of Aimmune Therapeutics marks an important milestone in our constant pursuit of innovative, science-bassed nutritional solutions to support …See details»
Aimmune Therapeutics - Products, Competitors, Financials, …
About Aimmune Therapeutics Aimmune Therapeutics develops treatments for food allergies using standardized, pharmaceutical-grade food allergens and characterized oral desensitization …See details»
Working at Aimmune Therapeutics: Employee Reviews - Indeed
Nov 19, 2024 Reviews from Aimmune Therapeutics employees about Aimmune Therapeutics culture, salaries, benefits, work-life balance, management, job security, and more.See details»
Nestlé commences tender offer for Aimmune Therapeutics, Inc.
Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements regarding Aimmune's business may include: the expectation that Aimmune will need additional …See details»
Aimmune Submits FDA Application to Offer AR101 for the …
Dec 21, 2018 Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 4–17 BRISBANE, Calif.– (BUSINESS …See details»
Monteverde & Associates PC and Kahn Swick & Foti, LLC …
2 days ago If you have not received the Notice of Pendency and Proposed Settlement of Class Action ("Notice") and the Proof of Claim and Release form, you may obtain copies by writing to …See details»
Nestlé commences tender offer for Aimmune Therapeutics, Inc.
Sep 14, 2020 Nestlé commences a cash tender offer to purchase all of the outstanding shares of common stock of Aimmune Therapeutics, Inc.See details»